Asia Deal Watch: Oxford Biomedica’s First Japanese Partnership Focuses On Rare Retinal Disorder
Executive Summary
Oxford Biomedica is teaming with Santen to develop a gene therapy for an undisclosed eye disease. Shionogi inks a pair of partnerships for Chinese rights to lusutrombopag and epertinib.
You may also be interested in...
China Ho! Sun Strikes Deals For Ilumya, Cequa
India's Sun has licensed out treatments for psoriasis and dry eye to a new partner for selected Asian markets and China, which it expects to emerge as a key market for its products.
Deal Watch: Gilead Partners With Carna On Small Molecule IO Drug Development
Partnership will use Carna’s proprietary lipid kinase drug discovery platform, bringing another aspect to Gilead’s IO efforts. Catalent continues expansion by acquiring Novavax R&D assets; Genfit licenses elafibranor in China to Terns.
Conditions Converging For More M&A In Korean Pharma, Biotech
Merger and acquisition deals in South Korea’s pharma/biotech sector have remained relatively few compared to other countries, but several factors are now pointing to a possible increase in activity as pharma and biotech firms hunt for new technologies and growth.